Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13107698 | 0.81 | KDM4E (0.42) | KDM4EMEN1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL26654935 | 0.81 | KDM4E (0.42) | KDM4EMEN1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL13995529 | 0.78 | KDM4E (0.39) | KDM4EMEN1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL13998247 | 0.78 | KDM4E (0.39) | KDM4EMEN1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL23027113 | 0.74 | KDM4E (0.37) | KDM4EMEN1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL26655281 | 0.74 | KDM4E (0.37) | KDM4EMEN1CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL23003285 | 0.73 | KDM4E (0.36) | KDM4EMEN1CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL23003281 | 0.73 | KDM4E (0.36) | KDM4EMEN1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL26655637 | 0.69 | NFE2L2 (0.34) | KDM4EMEN1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL21215169 | 0.68 | KDM4E (0.35) | KDM4EMEN1CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018052-A1 | Treatment of Diabetes and Related Pathologies | MEDICURE, INC. (CA) | 2009-01-15 | — | — | US | disclosed |
| US-20080139511-A1 | Combination Therapies Employing Ace Inhibitors and Uses Thereof for the Treatment of Diabetic Disorders | MEDICURE INTERNATIONAL INC. (BB) | 2008-06-12 | — | — | US | disclosed |
| EP-1897547-A1 | Use of pyridoxal phosphate derivatives for the treatment of diabetes and related complications | Medicure Inc. (CA) | 2008-03-12 | — | — | EP | disclosed |
| EP-1872797-A2 | Treatment of cardiovascular and related pathologies | Medicure International Inc. (BB) | 2008-01-02 | — | — | EP | disclosed |
| EP-1832291-A2 | use of pyridoxal phosphate for the treatment of diabetes and related complications | Medicure Inc. (CA) | 2007-09-12 | — | — | EP | disclosed |
| US-7230009-B2 | Pyridoxal analogues and methods of treatment | MEDICURE, INC. (CA) | 2007-06-12 | — | — | US | disclosed |
| US-20070060549-A1 | COMBINATION THERAPIES EMPLOYING ACE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DIABETIC DISORDERS | MEDICURE INTERNATIONAL INC. (CA) | 2007-03-15 | — | — | US | disclosed |
| US-7148233-B2 | Treatment of cardiovascular and related pathologies | MERRILL LYNCH CAPITAL CANADA INC. (CA) | 2006-12-12 | — | — | US | disclosed |
| US-7144892-B2 | Administering mixtures of heterocyclic imines, calcium channel blockers, adrenergic blocking agents, anticoagulants, diuretics and angiotensin converting enzyme inhibitors, for prophylaxis of heart diseases such as arrhythmias or necrosis | MERRILL LYNCH CAPITAL CANADA INC. (CA) | 2006-12-05 | — | — | US | disclosed |
| US-7132430-B2 | Treatment of cardiovascular and related pathologies | MEDICURE INTERNATIONAL INC. (BB) | 2006-11-07 | — | — | US | disclosed |
| US-20040033990-A1 | Treatment of cardiovascular and related pathologies | MEDICURE INTERNATIONAL INC. | 2004-02-19 | — | — | US | disclosed |
| US-20040033993-A1 | Treatment of cardiovascular and related pathologies | MEDICURE INTERNATIONAL INC. | 2004-02-19 | — | — | US | disclosed |
| US-6677356-B1 | CONCURRENTLY ADMINISTERING PYRIDOXAL-5'-PHOSPHATE, PYRIDOXAMINE, PYRIDOXAL, OR A 3-ACYLATED PYRIDOXAL ANALOGUE WITH ANGIOTENSIN CONVERTING ENZYME INHIBITOR,CALCIUM CHANNEL BLOCKER, ADRENERGIC BLOCKING AGENT, VASODILATOR OR DIURETIC | MEDICURE INTERNATIONAL INC. (KY) | 2004-01-13 | — | — | US | disclosed |
| US-20030195236-A1 | Pyridoxal analogues and methods of treatment | MEDICURE INC. (CA) | 2003-10-16 | — | — | US | disclosed |
| US-20030008847-A1 | Treatment of diabetes and related pathologies | MEDICURE, INC. (CA) | 2003-01-09 | — | — | US | disclosed |
| US-6489345-B1 | TREATING DIABETES MELLITUS IN A MAMMAL COMPRISING ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A 3-ACYLATED PYRICOXAL ANALOGUE OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | MEDICURE, INC. (CA) | 2002-12-03 | — | — | US | disclosed |
| EP-1210117-A2 | COMPOSITONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES CONTAINING PYRIDOXAL COMPOUNDS AND CARDIOVASCULAR COMPOUNDS | Medicure International Inc. (BB) | 2002-06-05 | — | — | EP | disclosed |
| US-6339085-B1 | FOR THERAPY OF HYPERTROPHY, HYPERTENSION, CONGESTIVE HEART FAILURE, MYOCARDIAL ISCHEMIA, ARRHYTHMIA, HEART FAILURE SUBSEQUENT TO MYOCARDIAL INFARCTION, MYOCARDIAL INFARCTION, ISCHEMIA REPERFUSION INJURY, BLOOD COAGULATION | THE UNIVERSITY OF MANITOBA (CA) | 2002-01-15 | — | — | US | disclosed |
| US-20010031770-A1 | Pyridoxal analogues and methods of treatment | MEDICURE INC. (CA) | 2001-10-18 | — | — | US | disclosed |
| WO-2001013900-A2 | COMPOSITIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES CONTAINING PYRIDOXAL COMPOUNDS AND CARDIOVASCULAR COMPOUNDS | MEDICURE INTERNATIONAL INC. (BB) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008847-A1 | Treatment of diabetes and related pathologies | PDXK, PNPO, IAPP | KDM4E 630/4885MEN1 2709/4885CYP1A2 2833/4885 |
| US-20070060549-A1 | COMBINATION THERAPIES EMPLOYING ACE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DIABETIC DISORDERS | ACE, ACE2, REN | KDM4E 2342/4885MEN1 2986/4885CYP1A2 478/4885 |
| US-20090018052-A1 | Treatment of Diabetes and Related Pathologies | PDXK, PNPO, IAPP | KDM4E 547/4885MEN1 2444/4885CYP1A2 2925/4885 |
| US-20040033990-A1 | Treatment of cardiovascular and related pathologies | PNPO, PLPBP, PDXK | KDM4E 1450/4885MEN1 2157/4885CYP1A2 817/4885 |
| US-20010031770-A1 | Pyridoxal analogues and methods of treatment | PNPO, PDXK, PLPBP | KDM4E 3235/4885MEN1 1325/4885CYP1A2 2491/4885 |
| US-20040033993-A1 | Treatment of cardiovascular and related pathologies | PLPBP, PDXK, PNPO | KDM4E 2180/4885MEN1 4247/4885CYP1A2 1427/4885 |
| US-20080139511-A1 | Combination Therapies Employing Ace Inhibitors and Uses Thereof for the Treatment of Diabetic Disorders | ACE, ACE2, REN | KDM4E 2342/4885MEN1 2986/4885CYP1A2 478/4885 |
| US-20030195236-A1 | Pyridoxal analogues and methods of treatment | PNPO, PDXK, PLPBP | KDM4E 3385/4885MEN1 1415/4885CYP1A2 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.